Understanding FDA’s Deficiency Response Letters for ANDA Submissions: A Guide to Successful Outcomes
Spread the love In the pharmaceutical industry, obtaining approval from the U.S. Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) is a critical step toward bringing generic drugs to market. However, this process often involves receiving deficiency response letters from the FDA. These letters—Discipline Review Letters (DRLs), Information Requests (IRs), and…






